Abstract
Selective inhibition of herpes simplex virus (HSV) type 1 replication but not of HSV type 2 replication by (E)-5-(2-bromovinyl)2'-deoxyuridine (BVDU) was utilized to differentiate clinical isolates of these viruses. BVDU (0.7 microgram/ml) reduced HSV type 1 PFU by an average of 2.74 log10, but had no effect on the plaque-forming ability of HSV type 2 isolates. The incorporation of BVDU into the media of primary cell cultures used for virus isolation in the clinical laboratory allowed for the correct presumptive identification of HSV types.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
